Please Wait
Applying Filters...
menu
    • menu
    LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.

    Virtual Booth

    Contact Supplier

    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2025-11-03

    Virtual Booth

    An Enquiry

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    Jai Radhe Sales is your partner for all your sourcing needs.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    An Enquiry

    Menu

    Relacorilant

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Corcept’s Relacorilant Benefits PARPi-Treated Ovarian Cancer
    Corcept’s Relacorilant Benefits PARPi-Treated Ovarian Cancer

    19 Oct 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20251019109551/en/Corcept-Presents-ESMO-2025-Late-Breaker-Relacorilant-Demonstrates-Benefit-in-Patients-with-Platinum-Resistant-Ovarian-Cancer-with-Prior-PARP-Inhibitor-Treatment

    BUSINESSWIRE
    19 Oct 2025
    Share Share
    Corcept Seeks EMA Approval For Relacorilant
    Corcept Seeks EMA Approval For Relacorilant

    14 Oct 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20251014154513/en/Corcept-Submits-Marketing-Authorization-Application-to-European-Medicines-Agency-for-Relacorilant-as-a-Treatment-for-Patients-with-Platinum-Resistant-Ovarian-Cancer

    BUSINESSWIRE
    14 Oct 2025
    Share Share
    Corcept Shares ROSELLA Trial Data in Ovarian Cancer at ESMO
    Corcept Shares ROSELLA Trial Data in Ovarian Cancer at ESMO

    22 Sep 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250922541539/en/Corcept-to-Present-New-Late-Breaking-Data-From-Pivotal-ROSELLA-Trial-of-Relacorilant-in-Platinum-Resistant-Ovarian-Cancer-at-ESMO-2025

    BUSINESSWIRE
    22 Sep 2025
    Share Share
    FDA Files Corcept’s Relacorilant for Platinum-Resistant Ovarian
    FDA Files Corcept’s Relacorilant for Platinum-Resistant Ovarian

    10 Sep 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250910770269/en/FDA-Files-Corcepts-New-Drug-Application-for-Relacorilant-as-a-Treatment-for-Patients-with-Platinum-Resistant-Ovarian-Cancer

    BUSINESSWIRE
    10 Sep 2025
    Share Share
    Corcept Submits NDA for Ovarian Cancer Drug Relacorilant
    Corcept Submits NDA for Ovarian Cancer Drug Relacorilant

    14 Jul 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250714921466/en/Corcept-Submits-New-Drug-Application-for-Relacorilant-as-a-Treatment-for-Patients-with-Platinum-Resistant-Ovarian-Cancer

    BUSINESSWIRE
    14 Jul 2025
    Share Share
    Corcept Shows Relacorilant Improves Survival In Ovarian Cancer
    Corcept Shows Relacorilant Improves Survival In Ovarian Cancer

    02 Jun 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250602291571/en/Corcept-Presents-Pivotal-Clinical-Data-in-ASCO-Late-Breaker-with-Simultaneous-Publication-in-The-Lancet-Relacorilant-Improves-Progression-Free-and-Overall-Survival-in-Patients-with-Platinum-Resistant-Ovarian-Cancer

    BUSINESSWIRE
    02 Jun 2025
    Share Share